918博天娱乐·(中国)官方网站

    Pipeline

    Product and Pipeline
    Indication
    Discovery
    (Pre-clinical-Phase II)
    Development
    (Phase III)
    Commercialization
    Dorzagliatin
    T2D - Drug Naïve
    T2D - Metformin Tolerated
    RWE study for Diabetes Remission
    Diabetes Prevention
    Neurodegeneration
    Dorzagliatin and Metformin FDC
    T2D
    Dorzagliatin + Empagliflozin
    DKD
    Dorzagliatin + Sitagliptin
    T2D
    Dorzagliatin add on to GLP1RA
    T2D and Obesity
    Dorzagliatin add on to Insulin
    T1D
    2nd Generation GKA
    Metabolic Disease
    mGLUR5 NAM
    PD-LID
    Drug Addiction
    GK NAM
    Metabolic Disease
    Dorzagliatin
    Discovery
    (Pre-clinical-Phase II)
    Development
    (Phase III)
    Commercialization
    T2D - Drug Naïve
    T2D - Metformin Tolerated
    RWE study for Diabetes Remission
    Diabetes Prevention
    Neurodegeneration
    Dorzagliatin and Metformin FDC
    Discovery
    (Pre-clinical-Phase II)
    Development
    (Phase III)
    Commercialization
    T2D
    Dorzagliatin + Empagliflozin
    Discovery
    (Pre-clinical-Phase II)
    Development
    (Phase III)
    Commercialization
    DKD
    Dorzagliatin + Sitagliptin
    Discovery
    (Pre-clinical-Phase II)
    Development
    (Phase III)
    Commercialization
    T2D
    Dorzagliatin add on to GLP1RA
    Discovery
    (Pre-clinical-Phase II)
    Development
    (Phase III)
    Commercialization
    T2D and Obesity
    Dorzagliatin add on to Insulin
    Discovery
    (Pre-clinical-Phase II)
    Development
    (Phase III)
    Commercialization
    T1D
    2nd Generation GKA
    Discovery
    (Pre-clinical-Phase II)
    Development
    (Phase III)
    Commercialization
    Metabolic Disease
    mGLUR5 NAM
    Discovery
    (Pre-clinical-Phase II)
    Development
    (Phase III)
    Commercialization
    PD-LID
    Drug Addiction
    GK NAM
    Discovery
    (Pre-clinical-Phase II)
    Development
    (Phase III)
    Commercialization
    Metabolic Disease
    Focus Us
    Copyright © 2024  Hua Medicine (Shanghai) Co., Ltd.    互联网药品信息服务资格证书编号: (沪)-非经营-2022-0079
    沪ICP备14036654号-1  beiantubiao.png 沪公网安备 31011502013809号  Privacy Statement  Terms of Use
    Search
    How we use cookies
    Hua Medicine uses cookies to enable and improve the use of the website. By continuing to use the site, you consent to the use of these cookies. To learn more about cookies, please read our privacy statement.
    Accept
    x
    友情链接: